re: Ann: Axiron Net Sales for the Quarter to ... From the release:
"The US testosterone replacement therapy market has been impacted and unless this improves and/or Axiron’s share of market increases, the next milestone may not be met in calendar year 2014. The $50 million milestone remains payable in the first calendar year that the global sales hurdle is met. Axiron has been launched in Canada, Australia,
Germany and Brazil, and is approved in Korea and launch is planned for end of June. "
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(5.26%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $11.58K | 619.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 335415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 516258 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |